Physician profile
Anthony M Turkiewicz
NPI 1558384024
$2,165,813.32
in general payments reported to CMS, 2019-2025
42 companies · $256K in 2025
The $256K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518K · 2020: $248K · 2021: $235K · 2022: $317K · 2023: $327K · 2024: $265K · 2025: $256K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $617K · Travel and Lodging: $138K · Consulting Fee: $67K · Food and Beverage: $25K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $617,395.25 |
| Travel and Lodging | $138,051.08 |
| Consulting Fee | $66,916.50 |
| Food and Beverage | $25,093.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649,646.86 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $299,953.99 | 2019-2025 | Taltz |
| Janssen Biotech, INC. | $286,857.13 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Janssen Scientific Affairs, LLC | $218,663.37 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $175,410.68 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $144,047.79 | 2021-2025 | Saphnelo |
| Pfizer INC. | $127,284.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $124,296.59 | 2019-2025 | |
| Genzyme Corporation | $47,222.79 | 2020-2025 | |
| Amgen INC. | $31,553.85 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Regeneron Healthcare Solutions, INC. | $23,631.73 | 2019 | |
| Eli Lilly and Company | $15,065.22 | 2019 | |
| Novartis Pharma Ag | $10,916.17 | 2019 | |
| Averitas Pharma INC. | $5,454.15 | 2023 | |
| Horizon Therapeutics Plc | $1,640.00 | 2019-2023 | Krystexxa |
Show all 40 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Turkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.